Share-based Payment Arrangement, Expense of Revance Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Revance Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $4,582,000, a 49% decline year-over-year.
  • Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $35,216,000, a 20% decline year-over-year.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49,187,000, a 6% decline from 2022.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $52,340,000, a 21% increase from 2021.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $43,434,000, a 19% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $35,216,000 $4,582,000 -$4,328,000 -49% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $39,544,000 $6,032,000 -$7,454,000 -55% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $46,998,000 $8,763,000 -$2,189,000 -20% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $49,187,000 $15,839,000 +$5,112,000 +48% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 $44,075,000 $8,910,000 -$9,077,000 -50% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $53,152,000 $13,486,000 +$4,223,000 +46% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $48,929,000 $10,952,000 -$3,411,000 -24% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $52,340,000 $10,727,000 -$194,000 -1.8% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $52,534,000 $17,987,000 +$7,449,000 +71% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $45,085,000 $9,263,000 -$2,105,000 -19% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $47,190,000 $14,363,000 +$3,756,000 +35% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $43,434,000 $10,921,000 -$958,000 -8.1% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $44,392,000 $10,538,000 -$139,000 -1.3% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $44,531,000 $11,368,000 +$4,015,000 +55% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $40,516,000 $10,607,000 +$4,063,000 +62% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $36,453,000 $11,879,000 +$6,839,000 +136% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $29,614,000 $10,677,000 +$6,374,000 +148% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $23,240,000 $7,353,000 +$2,933,000 +66% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $20,307,000 $6,544,000 +$2,385,000 +57% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $17,922,000 $5,040,000 +$1,189,000 +31% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $16,733,000 $4,303,000 +$211,000 +5.2% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $16,522,000 $4,420,000 +$248,000 +5.9% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $16,274,000 $4,159,000 +$1,000 +0.02% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $16,273,000 $3,851,000 +$441,000 +13% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $15,832,000 $4,092,000 +$946,000 +30% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 $14,886,000 $4,172,000 +$653,000 +19% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $14,233,000 $4,158,000 +$1,003,000 +32% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $13,230,000 $3,410,000 +$441,000 +15% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $12,789,000 $3,146,000 +$391,000 +14% 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2018 2018 Q3
Q2 2017 $12,398,000 $3,519,000 +$267,000 +8.2% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $12,131,000 $3,155,000 +$178,000 +6% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $11,953,000 $2,969,000 -$2,105,000 -41% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $14,058,000 $2,755,000 +$165,000 +6.4% 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2017 2017 Q3
Q2 2016 $13,893,000 $3,252,000 +$845,000 +35% 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2017 2017 Q2
Q1 2016 $13,048,000 $2,977,000 +$660,000 +28% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $12,388,000 $5,074,000 +$3,138,000 +162% 01 Oct 2015 31 Dec 2015 10-K 02 Mar 2018 2017 FY
Q3 2015 $9,250,000 $2,590,000 +$305,000 +13% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 $8,945,000 $2,407,000 +$908,000 +61% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 $8,037,000 $2,317,000 +$1,507,000 +186% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $6,530,000 $1,936,000 01 Oct 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
Q3 2014 $2,285,000 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015 2015 Q3
Q2 2014 $1,499,000 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $810,000 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

Revance Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $49,187,000 -$3,153,000 -6% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $52,340,000 +$8,906,000 +21% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $43,434,000 +$6,981,000 +19% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $36,453,000 +$18,531,000 +103% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $17,922,000 +$1,649,000 +10% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $16,273,000 +$3,043,000 +23% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $13,230,000 +$1,277,000 +11% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $11,953,000 -$435,000 -3.5% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $12,388,000 +$5,858,000 +90% 01 Jan 2015 31 Dec 2015 10-K 02 Mar 2018 2017 FY
2014 $6,530,000 +$5,982,000 +1092% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $548,000 +$469,000 +594% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 $79,000 01 Jan 2012 31 Dec 2012 10-K 04 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.